Alon Gurfinkel
Lawyers

Filters
Gracell Biotechnologies $209 million IPO and Nasdaq listing
We advised the underwriters on the IPO of ADSs
iQIYI $1.5 billion concurrent convertible notes and equity offerings
Davis Polk advised the joint book-running managers in connection with concurrent SEC-registered offerings by iQIYI, Inc. of $800 million aggregate principal amount of its 4.00%…
PLAID IPO and TSE listing
Davis Polk advised PLAID, Inc., a Japan-based SaaS customer experience (CX) solutions provider, in connection with its initial public offering of 14,339,000 shares of common stock and Tokyo…
Roland ¥36.3 billion IPO and TSE listing
Davis Polk advised the international joint lead managers in connection with the initial public offering of 11,710,000 shares of common stock of Roland Corporation. The shares were sold by…
ANA HOLDINGS ¥305.2 billion global stock offering
Davis Polk advised the joint global coordinators in connection with the global offering of 140,000,000 shares of common stock of ANA HOLDINGS INC., which included over-allotment…
Commonwealth Bank of Australia cash tender offers
Davis Polk advised the dealer managers in connection with cash tender offers by Commonwealth Bank of Australia to purchase certain of its outstanding debt securities.
Headquartered in…
Pop Mart HK$5.2 billion IPO and Hong Kong listing
Davis Polk advised Pop Mart International Group Limited in connection with its initial public offering and listing on the Hong Kong Stock Exchange and an international offering in reliance…
Dexin China Holdings $200 million high-yield notes offering and tender offer
Davis Polk advised the initial purchasers in connection with a Regulation S offering by Dexin China Holdings Company Limited of its $200 million 9.950% senior notes due 2022.
Concurrently…
Prosus $1.5 billion notes offering and €600 million notes reopening
Davis Polk advised the initial purchasers in connection with a Rule 144A/Regulation S offering by Prosus N.V. of $1.5 billion principal amount of 3.832% notes due 2051 under its $6 billion…
Notre Dame Intermédica R$3.8 billion equity offering
Davis Polk advised Notre Dame Intermédica Participações S.A. in connection with the equity offering by Bain Capital, the controlling shareholder of Notre Dame Intermédica, of 54,000,000…